Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years
Ken Song almost never got into radiopharmaceuticals. But after back-to-back phone calls from venture capital leaders at Versant and venBio in March 2020, the repeat life sciences CEO took a deep dive into the field, which at that point was outside the radar of most people in drug development. Those calls worked, and Song would […]
